A Study of IN026 in Participants With Refractory Gout

NCT07587684 — Phase 1, Recruiting, 16 participants, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

A Clinical Study on the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of IN026 in the Treatment of Refractory Gout

Registry	NCT07587684
Status	Recruiting
Phase	Phase 1
Study type	Interventional; non randomized, sequential, masking: none, treatment
Enrollment	16 (Estimated)
Sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Other)
Conditions	Refractory Gout
Interventions	IN026 Injection (Drug)
Dates	start 2026-06-12, primary completion 2027-08-01 (estimated), completion 2028-05-01 (estimated), first posted 2026-05-14, last updated 2026-07-31
Locations	1 site in China

-Summary

The goal of this clinical study is to learn if IN026 Injection is safe and works to lower uric acid levels in adults with refractory gout (gout that does not respond well to standard treatments). The main questions it aims to answer are:

* What medical problems do participants have when taking IN026, such as changes in vital signs, blood tests, or heart rhythm?
* How does the body absorb, process, and respond to IN026, and does it trigger an immune reaction?
* Does IN026 lower uric acid levels in the blood and reduce tophi?

Investigator will start with lower doses of IN026 and slowly increase the dose to find the well-tolerated dose.

Participants will:

* Receive IN026 through an intravenous (IV) drip into a vein at a set dose.
* Complete a screening period of up to 4 weeks, followed by treatment and check-ups for up to 20 weeks.
* Have blood and urine samples taken at set times to check safety and how the body responds to IN026.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
IN026 at Dose-Level A	Experimental	Drug: IN026 Injection	Participants receive intravenous IN026 Injection at dose-level A on Week 1 Day 1 (W1D1). Following safety/tolerability assessment, participants may receive extra doses (up to 5 in total) at predefined frequency.
IN026 at Dose-Level B	Experimental	Drug: IN026 Injection	Participants receive intravenous IN026 Injection at dose-level B on Week 1 Day 1 (W1D1). Following safety/tolerability assessment, participants may receive extra doses (up to 5 in total) at predefined frequency.
IN026 at Dose-Level C	Experimental	Drug: IN026 Injection	Participants receive intravenous IN026 Injection at dose-level C on Week 1 Day 1 (W1D1). Following safety/tolerability assessment, participants may receive extra doses (up to 5 in total) at predefined frequency.
IN026 at Dose-Level D	Experimental	Drug: IN026 Injection	Participants receive intravenous IN026 Injection at dose-level D on Week 1 Day 1 (W1D1). Following safety/tolerability assessment, participants may receive extra doses (up to 5 in total) at predefined frequency.
IN026 at Dose-Level E	Experimental	Drug: IN026 Injection	Participants receive intravenous IN026 Injection at dose-level E on Week 1 Day 1 (W1D1). Following safety/tolerability assessment, participants may receive extra doses (up to 5 in total) at predefined frequency.
IN026 at Dose-Level F	Experimental	Drug: IN026 Injection	Participants receive intravenous IN026 Injection at dose-level F on Week 1 Day 1 (W1D1). Following safety/tolerability assessment, participants may receive extra doses (up to 5 in total) at predefined frequency.

IN026 Injection (Drug): IN026 Injection is a lipid nanoparticle (LNP)-formulated mRNA therapeutic administered as an intravenous (IV) infusion

+Outcome measures

Primary outcomes

Incidence of Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs) [From first dose (Week 1 Day 1) through end of study (Week 21)]

Secondary outcomes

Change from Baseline in Serum Uric Acid Concentration [From baseline (Week 1 Day 1) through Week 21]
Change in Tophi from Baseline [From baseline (Week 1 Day 1) through Week 21]
Plasma Concentration of IN026 mRNA Over Time [At pre-specified timepoints from first dose (Week 1 Day 1) through Week 21]
Plasma Concentration of Ionizable Lipid SX-66 Over Time [At pre-specified timepoints from first dose (Week 1 Day 1) through Week 21]
Serum Uricase Level Over Time [At pre-specified timepoints from first dose (Week 1 Day 1) through Week 21]
Serum Uric Acid Level Over Time [At pre-specified timepoints from first dose (Week 1 Day 1) through Week 21]
Serum Allantoin Level Over Time [At pre-specified timepoints from first dose (Week 1 Day 1) through Week 21]
Titer of Anti-Drug Antibodies (ADAs) Over Time [At pre-specified timepoints from first dose (Week 1 Day 1) through Week 21]

+Eligibility

Sex: All, ages: 18 Years to 75 Years

Inclusion Criteria:

1. Can voluntarily sign the informed consent form (ICF) and comply with ICF and study protocol requirements.
2. Male or female, 18-75 years old (inclusive) at screening.
3. Meet 2015 ACR/EULAR gout classification criteria, in the intercritical phase of gout or acute flare resolved ≥2 weeks at screening.
4. Serum uric acid ≥420 μmol/L (7 mg/dl) at screening.
5. Meet the definition of refractory gout (poor uric acid control accompanied by severe gout symptoms)

Exclusion Criteria:

1. Gout secondary to radiotherapy/chemotherapy, lead poisoning, organ transplantation, tumor, etc. at screening/baseline.
2. Rheumatoid arthritis, infectious/septic arthritis, or other acute inflammatory arthritis at screening/baseline.
3. Glucose-6-phosphate dehydrogenase (G6PD) deficiency history, or G6PD level below normal lower limit.
4. Positive HBsAg; HCV antibody positive is excluded except those with sustained HCV-RNA negativity after standard treatment; HIV antibody positive; active syphilis.
5. Presence of chronic liver diseases including active hepatitis, cirrhosis and alcoholic liver disease.
6. Participants with a history of any of the following: serious cardiovascular diseases within 6 months prior to screening; or serious diseases of the digestive, respiratory, urinary, musculoskeletal, neuropsychiatric, hematological, or immune systems within 3 months prior to screening.
7. Prolonged QTcF at screening.
8. Uncontrolled or untreated hypertension at screening.
9. Participants who have received medications that may affect endpoint assessment, such as other urate-lowering therapies, mRNA-LNP vaccine, PEGylated drugs and uricase agents.
10. History of severe allergy, or known allergy to IN026 or its components.
11. Participation in other clinical trials within 30 days prior to screening.
12. Participants with poor compliance, or those deemed otherwise unsuitable for this study by the investigator.

+Locations (1)

Facility	City	Country	Status
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	Recruiting

+Investigators

QiuBai Li, Principal investigator, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology